Promoting osteogenic differentiation and efficacious bone regeneration have the potential to revolutionize the treatment of orthopaedic and musculoskeletal disorders. Mesenchymal Stem Cells (MSCs) are bone marrow progenitor cells that have the capacity to differentiate along osteogenic, chondrogenic, myogenic, and adipogenic lineages. Differentiation along these lineages is a tightly controlled process that is in part regulated by the Bone Morphogenetic Proteins (BMPs). BMPs 2 and 7 have been approved for clinical use because their osteoinductive properties act as an adjunctive treatment to surgeries where bone healing is compromised. BMP-9 is one of the least studied BMPs, and recent in vitro and in vivo studies have identified BMP-9 as a potent inducer of osteogenic differentiation in MSCs. BMP-9 exhibits significant molecular cross-talk with the Wnt/ -catenin and other signaling pathways, and adenoviral expression of BMP-9 in MSCs increases the expression of osteogenic markers and induces trabecular bone and osteiod matrix formation. Furthermore, BMP-9 has been shown to act synergistically in bone formation with other signaling pathways, including Wnt/ -catenin, IGF, and retinoid signaling pathways. These results suggest that BMP-9 should be explored as an effective bone regeneration agent, especially in combination with adjuvant therapies, for clinical applications such as large segmental bony defects, non-union fractures, and/or spinal fusions.
INTRODUCTION
Efficacious bone regeneration could revolutionize the management of bone and musculoskeletal disorders. Bone is one of the few organs that retains its potential for continued regeneration into adult life and is the only tissue that undergoes continual remodeling throughout life [1] [2] . In 2000, there were more physician visits for musculoskeletal complaints than any other condition [3] . Nearly 56 million physician visits are made each year for musculoskeletal complaints, which accounts for over 60 percent of all injuryrelated visits and nearly 215 billion dollars in annual health care costs [1, 3] . In fact, the United Nations and World Health Organization has declared 2000-2010 the "Bone and Joint Decade" to promote awareness of bone and musculoskeletal disorders [1] .
*Address correspondence to this author at the Molecular Oncology Laboratory, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC 3079, Chicago, IL 60637, USA; Tel: (773) 702-7169; Fax (773) 834-4598; E-mail: tche@surgery.bsd.uchicago.edu While most fractures in healthy individuals heal spontaneously, failures in this regenerative process can lead to significant patient morbidity. Efficacious bone regeneration is thus critical to the management of bone and musculoskeletal disorders, and there are at least three common clinical scenarios where there is an identified need to augment bone regeneration. (1) Segmental bone loss is a common problem given the increase in revision joint arthroplasty, musculoskeletal trauma, and large bone tumor resection which frequently leaves orthopedic patients with critical sized defects that cannot heal spontaneously [4] . In such patients, various forms of augmentation are necessary to repair these critical sized defects. (2) Fracture non-union or delayed union will occur in approximately 5-10% of the 5.6 million patients who sustain a fracture annually [5] . While various factors can contribute to impaired healing, there are also numerous clinical options to treat non-union, including bone allograft, bone autograft, and treatment with recombinant bone morphogenetic proteins (BMPs) [6] [7] [8] [9] [10] . Nonetheless, the poor patient outcomes associated with fracture non-union suggest a critical need for more efficacious strategies for bone regeneration. (3) Spinal fusions are performed nearly 200,000 times each year, and failure to achieve bony union occurs in 10-40% of patients with single level fusions [11] . Current surgical protocols use autologous bone graft from the iliac crest to achieve bony union, however, harvesting such a graft poses complication risks and does not necessarily guarantee spinal fusion [11] . These clinical scenarios underscore the need to develop novel strategies to enhance bone regeneration in the treatment of musculoskeletal disorders.
Recent studies have identified BMPs as potent inducers of osteogenesis. Several forms of recombinant BMPs (rhBMPs), most notably rhBMP-2 and rhBMP-7, have been tested in clinical trials and are now used as adjunctive therapy in the clinical setting [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Data from these trials suggest that BMP-induced bone formation is at least equivalent to autologous bone-grafting in treatment of non-unions and spinal fusions [24] [25] . However, it has been unclear whether rhBMP-2 and 7 are in fact the most potent BMPs in inducing osteogenesis. Recent studies have suggested that BMP-9, one of the least studied BMPs, is a more potent inducer of osteogenic differentiation both in vitro and in vivo, and should be further investigated as an adjunctive treatment for bone regeneration.
BONE MORPHOGENETIC PROTEINS (BMPS) AS IMPORTANT BONE FORMING FACTORS
During skeletogensis, bone formation occurs through either intramembranous or endochondral ossification [26] . Intramembranous ossification occurs in flat bones and involves direct condensation of mesenchymal stem cells (MSCs) [27] [28] . Endochondral ossification is characterized by sequential phases in which MSCs form a cartilaginous matrix followed by subsequent ossification [27] [28] [29] . Bone regeneration following a fracture progresses through sequential phases similar to endochondral ossification, starting with migration and proliferation of MSCs [2] . Although the molecular events underlying bone regeneration remain largely unclear, two key steps are the osteoinduction of MSCs to become bone-forming osteoblasts, and the differentiation of these osteoblasts to produce osteoid matrix [1] . The identification of BMPs has generated great interest because they play a crucial role in regulating these steps of bony regeneration. Due to their osteoinductive capabilities, BMPs hold tremendous therapeutic potential for the treatment of bone and musculoskeletal disorders.
It has been long established that demineralized bone can induce de novo bone formation [30] . The molecular identity of these bone forming factors was subsequently revealed to be BMPs [31] . As members of the transforming growth factor beta TGF-superfamily, BMPs play a critical role in skeletal development, bone formation, cellular differentiation, and stem cell biology. [32] [33] [34] [35] . For example, BMPs 4, 7, 8, and 15 play roles in reproductive tissue development; BMPs 2, 4, and 7 mediate cartilage regeneration, and BMPs 12 and 13 are crucial in tendon healing [36] [37] [38] [39] [40] [41] [42] . At least 15 types of BMPs have been identified in humans, and genetic disruptions of BMPs result in various skeletal and extraskeletal abnormalities [43] [44] . BMP signal transduction begins with binding to the heterodimeric complex of two transmembrane serine/threonine kinase receptors, BMPR type 1 and BMPR type 2 [45] [46] . These activated receptor kinases transduce the signal by phosphorylating the transcription factors Smad 1, 5, and/or 8 [32] . The phosphorylated Smads then form a heterodimeric complex with Smad 4 in the nucleus and activate the transcription of target genes [47] [48] [49] .
While the exact molecular mechanisms underlying osteogenesis remain relatively unclear, studies have shown that BMPs play a crucial role in osteogenic differentiation. Numerous reports have confirmed that adenoviral, retroviral, or recombinant BMP application induces bone formation in animal models, and these osteoinductive properties have led to the use of rhBMPs as a mainstay in clinical bone regeneration [17, 19, 21, 23, [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] . In particular, rhBMP2 and rhBMP7 have been extensively used to augment bony healing [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , and administration of rhBMP 2 or rhBMP 7 leads to better fusion rates than autografts, successful bony union, and minimal associated complications [11, [24] [25] [67] [68] [69] [70] . Though much attention has been directed to rhBMPs 2 and 7 in bone regeneration, it is unclear whether these are actually the most osteogenic BMPs. An extensive analysis of the osteogenic activity of the 14 BMPs was previously impossible because recombinant forms of all BMPs were not readily available. Our lab recently conducted a comprehensive analysis of the in vivo and in vitro osteogenic activity of 14 BMPs using adenoviral mediated gene delivery into mesenchymal stem cells (MSCs) [4, 36, 71] . Our results demonstrated that BMP-2, BMP-6, and BMP-9 (BMP-7 to a lesser extent) were the most osteogenic BMPs [4, 36, 71] . Furthermore, BMP-9, one of the least studied BMPs, demonstrated the most potent induction of the osteogenic phenotype in MSCs [4, 71] . These findings suggest that BMP-9 could represent an equally, if not more effective, strategy for augmentation of bone regeneration in the clinical setting.
BONE MORPHOGENETIC PROTEIN 9 (BMP-9) AS ONE OF THE MOST POTENT BONE FORMING BMPS
BMP-9 (also known as growth differentiation factor 2, or GDF-2) was originally isolated from fetal mouse liver cDNA libraries and is a relatively uncharacterized member of the BMP family [72] . It is highly expressed in the developing mouse liver and is a potent stimulant of hepatocyte proliferation [72] . Other roles include inducing and maintaining the cholinergic phenotype of basal forebrain neurons, inhibiting hepatic glucose production, stimulating murine hepcidin 1 expression, and inducing critical enzymes of lipid metabolism [73] [74] [75] . BMP-9 is also a potent synergistic factor for hematopoietic progenitor cell generation and colony formation [76] . Although the exact role of BMP-9 in the skeletal system is unclear, it is one of the most potent BMPs in inducing osteogenic differentiation of MSCs both in vitro and in vivo [4, 36, [77] [78] [79] [80] . Furthermore, we have demonstrated in previous studies that BMP-9 regulates a distinct set of downstream targets that likely play a role in osteoinduction [36, [78] [79] [80] [81] . Unlike other members of the TGF-superfamily, the mature BMP-9 protein retains an N-terminal pro-region that is usually cleaved in BMPs prior to secretion. Interestingly, cell-based assays have shown that this pro-region causes no functional inhibition of BMP-9 and may actually function to stabilize the mature protein after secretion [35, [43] [44] [82] [83] [84] [85] [86] [87] . BMP-9 also demonstrates poor affinity for BMPR-IA, a receptor that typically transduces BMP signaling [82] . Taken together, these results suggest that BMP-9 mediated osteoinduction of MSCs likely occurs via a different mechanism than other osteogenic BMPs.
MESENCHYMAL STEM CELLS AS IMPORTANT OSTEOGENIC PROGENITORS
Mesenchymal Stem Cells (MSCs) are bone marrow stromal cells that can differentiate into osteogenic, chondrogenic, adipogenic, or myogenic lineages [36, [88] [89] [90] . Osteoblastic differentiation is a complex, tightly regulated process that is critical for proper bone formation and is influenced by a variety of endogenous and environmental factors, including BMPs, PPAR , Runx2, and Wnt/ Catenin [91] [92] .
The BMP family of growth factors is a pivotal regulator of early MSC commitment to osteogenesis. Osteogenic BMPs include 2,4,6,7 and 9, with BMP-9 showing the most potent osteogenic activity both in vitro and in vivo Figs. (1A and 1B) [1, 27, 29, 32-33, 36, 71, 90-92] . Exposure of MSCs to the osteogenic BMPs results in increased expression of osteoblast specific markers such as connective tissue growth factor (CTGF), Inhibitor of DNA Binding (Id), Alkaline Phosphatase (ALP) and Cbfa1/Runx2 [36, [78] [79] [80] [93] [94] [95] . PPAR is upregulated by the osteogenic BMPs, and PPAR knockout mice show decreased osteogenic differentiation in response to BMP stimulation [71, 78, 91] . The runt-related transcription factor 2 (Runx 2) is another one of the master regulatory genes in MSC osteoblast differentiation [28, 90, [96] [97] . Runx 2 -/-mice died shortly after birth with a cartilaginous skeleton that showed complete absence of ossification [98] . Furthermore, histologic analysis demonstrates delayed chondrocyte maturation, suggesting an important role for Runx 2 in both osteogenesis and chondrogenesis [99] . Finally, the Wnt signaling pathway is a strong inducer of MSC differentiation into osteoblasts [90, [100] [101] [102] [103] . Wnt genes are expressed in developing limbs and the Wnt coreceptor LR5 has been shown to regulate bone formation [90, [104] [105] [106] . Overexpression of a Wnt antagonist leads to the presence of lytic bone lesions, while overexpression of Wnt/ -Catenin signaling is frequently observed in osteosarcoma [107] [108] .
While osteogenic differentiation of MSCs is a complex multi-stage process, markers of this osteoblastic differentiation have been extensively documented in previous studies. Such markers include include CTGF (early), ALP and Runx2 (early/middle), and Osteopontin (OPN)/ Osteocalcin (OCN) (late) [1, 36, [91] [92] [109] [110] [111] [112] [113] [114] . By analyzing the levels of these early and late osteogenic markers, we can determine the osteoinductive properties of BMP treated MSCs.
BMP-9 INDUCES EFFECTIVE OSTEOGENIC DIFFERENTIATION AND BONE REGENERATION
Recent studies have shown strong evidence for BMP-9-induced osteogenic differentiation Figs. (1A and 1B). Adenoviral expression of BMP-9 in C3H10T1/2 cells in vitro resulted in a 181-fold increase in alkaline phosphatase activity nine days after infection. In fact, increases in alkaline phosphatase activity were observable as early as five days post infection [77] . Similar induction of alkaline phosphatase was also seen in preosteoblastic C2C12 cells and osteoblastic TE85 cells [77] . RT-PCR of BMP-9-stimulated C2C12 cells demonstrated increased expression of the late osteoblastic marker osteocalcin, and Alizarin Red immunohistochemical staining demonstrated the presence of mineralized osteoid nodules [77] . The induction of these osteogenic markers was significantly greater in BMP-9 treated cells than in BMP-2 or BMP-7 treatment groups [4, 77] . Furthermore, BMP-3, a known inhibitor of BMP-2 and BMP-7 mediated osteogenesis, had no inhibitory effect on BMP-9 mediated bone formation [4] . In other studies, non-adenoviral delivery of BMP-9 also demonstrated potent osteoinduction of MSCs [115] [116] [117] . Sheyn et al. found that sonoporation of rhBMP-9 into the thigh musculature of transgenic mice resulted in bone tissue formation, as demonstrated by micro-CT and histology [116] . Aslan et al. showed that nucleofection of hMSCs with BMP-9 induced bone formation 4 weeks post injection [117] . In another study by Bergeron et al., osteoinductive effects were demonstrated with a peptide derived from BMP-9 (pBMP-9). Treatment of MC3T3-E1 preosteoblastic cells with pBMP-9 induced downstream Smad phosphorylation that was not inhibited by noggin, an extracellular antagonist of BMP-2 [118] . pBMP-9 also caused a dose-dependent increase in alkaline phosphatase activity and quantitative realtime PCR demonstrated activation of the osteogenic genes Runx2, Osterix, Type 1 Collagen 1, and Osteocalcin as early as day 6 [118] .
In vivo studies have further confirmed BMP-9 as a potent inducer of bone formation. Athymic nude mice injected with BMP-9 transduced C2C12 cells show significant orthotopic bone formation on X-ray and histologic evaluation [4] . Recently, studies have suggested that skeletal muscle may harbor pluripotent MSCs and osteoblastic progenitor cells [56, 66, 119] ; when BMP-9 was injected intramuscularly in athymic nude mice, there was evidence of osteoid matrix production and mature lamellar bone [4] . Furthermore, BMP-9 injected groups demonstrated more diffuse ossification than both BMP-2 and BMP-7 treated groups. Similar in vivo results were seen when AdBMP-9 was injected percutaneously into thigh musculature of Sprague-Dawley rats. 3 days after injection, AdBMP-9 induced bone formation, and by day 9, ectopic ossification was visible on CT scan [120] . At its endpoint, BMP-9 induced the formation of significant amounts of ectopic bone that was histologically determined to be the result of normal endochondral mechanisms [120] . BMP-9 has also shown great success for inducing spinal fusion and non-union bone fracture repair in animal models [121] [122] . In a study by Dumont et al., sixteen athymic nude rats received a percutaneous paraspinal injection of BMP-9 transduced MSCs. 8 weeks after injection, CT scans and histological analysis of the lumbrosacaral spine clearly demonstrated large volumes of ectopic bone formation, successful spinal fusion, and no evidence of nerve root compression or local toxicity [121] . In a 2011 study by Bleich et al., nonunion fracture was created in the radii of C3H/HeN mice and filled with a collagen sponge electroporated with BMP-9 plasmid at the defect site [122] . Micro CT and histologic analysis of these BMP-9 electroporated radii showed bone formation bridging the defect gap and healing the nonunion [122] .
Histologically, BMP-9 induced bone formation demonstrates a unique ossification pattern from other BMPs. Kang et al. examined the histology of orthotopic bone formation in athymic nude mice injected with AdBMP-2, 6, 7, and 9-transduced C2C12 cells at 3 weeks [4] . The BMP-9 treated MSCs demonstrated varying degrees of ossification with multiple foci of immature woven bone, while BMP-2 sections should significantly less ossification [4] . Focal cartilaginous differentiation with bone marrow elements and cartilaginous matrix was also increased in the AdBMP-9 group [4] . In a similar study, Varady et al. conducted a morphologic analysis of BMP-9 gene therapy induced osteogenesis in both athymic nude mice and Sprague-Dawley rats [21] . AdBMP-9 was injected intramuscularly and morphologic analysis using light microscopy, electron microscopy, BrdU immunohistochemistry and microCT was performed at various time points. Primitive mesoderm could be seen infiltrating muscle fibers as early as 3 days after BMP-9 injection. At 6 days, MSCs differentiated into primitive chondroblasts that secreted a loose extracellular matrix, and by 9 days, virtually all recruited MSCs had differentiated into chondroblasts. At 12 days, regions of hypertrophied chondrocytes were observed that were strikingly similar to the end plates of the epiphysis. Finally, over the next week, the cartilaginous matrix was replaced by woven bone which was subsequently converted into mature bone [21] . These histologic analyses demonstrate that the process of BMP-9 induced osteogenesis is remarkably similar to the sequential phases of endochondral ossification that occurs during physiologic repair of bony fractures. In combination with the in vitro and in vivo evidence, these results suggest that BMP-9 may be a more efficacious therapy than BMP-2 or BMP-7 in inducing bone regeneration in the clinical setting. While the exact mechanism of BMP-9 mediated osteogenesis is still not clearly defined, it is likely that the BMP-9 osteogenic pathway is unique from that of other BMPs.
MOLECULAR MECHANISM OF BMP-9 MEDIATED BONE FORMATION
Increasing evidence suggests BMP-9 mediated osteogenesis occurs via overlapping but distinct signaling pathways than other BMPs Fig. (1C) . As previously mentioned, BMP-9 induces phosphorylation and activation of the Smad signaling pathway; however, the extracellular antagonist noggin is unable to inhibit BMP-9 signal transduction as it typically does with BMP-2 signaling [118] . Furthermore, we have demonstrated in previous studies that BMP-3, a known inhibitor of BMP-2 and BMP-7 osteogenesis, has no effect on BMP-9 mediated bone formation [4] . Subsequent studies investigating BMP-9 osteogenesis have identified unique signaling pathways that are essential for BMP-9 mediated osteoinduction.
TGF /BMP Type I and Type II Receptors Required for BMP-9 Signaling in MSCs
BMP signaling activity initiates with binding to type I and type II TGF-receptors. This interaction brings the two receptors into close proximity and allows the constitutively active type II receptor to cross phosphorylate the type I receptor, thereby triggering downstream signaling [123] . While ALK 1, ALK5, and endoglin have been reported as potential BMP-9 type I receptors, only recently has data elucidated the receptors necessary for BMP-9 mediated osteogenesis [82, [124] [125] [126] . Luo et al. conducted a comprehensive analysis of the seven functional type I receptors in BMP-9 induced osteogenic differentiation of MSCs. Dominant negative mutation of the seven type I receptors showed that only ALK1 and ALK2 mutants effectively inhibited BMP-9 osteogenic differentiation in vitro and ectopic bone formation in vivo [76] . Protein fragment complementation demonstrate that ALK 1 and ALK 2 interact directly with BMP-9, while RNAi silencing of ALK 1 and 2 inhibited BMP-9 induced Smad signaling and osteogenic differentiation [76] . These findings strongly suggest that ALK 1 and ALK 2 are the type I TGF receptors that are necessary for osteogenic BMP-9 signaling.
Currently, four different type II TGF receptors have been identified, including TGF RII, ActRII, ActRIIB, and BMPRII. Several studies have demonstrated that the functional type II TGF receptors are responsible for the osteogenic activity of BMPs, and a recent study by Wu et al. elucidated the specific type II receptors necessary for BMP-9 mediated osteogenesis [127] . In this study, dominant negative (DN) type II TGF receptors were introduced into C3H10 MSCs to determine which receptors were necessary for in vitro and in vivo BMP-9 induced osteogenesis. The study demonstrated that DN-BMPRII and DN-ActRII diminished BMP-9 induced alkaline phosphatase activity, Smad binding element (SBE) reporter activity, expression of downstream Smad 6 and Smad 7, and ectopic bone formation in vivo [127] . These findings strongly suggest that BMPRII and ActRII are the functional type II TGF receptors necessary to transduce BMP-9 osteogenic signaling.
Important Mediators of BMP-9 Induced Osteogenic Signaling

Inhibitors of Differentiation (Ids) HLH Factors
Id genes were originally identified in developing myoblasts, where they inhibited the binding of basic helixloop-helix (bHLH) transcription factors to muscle specific genes [128] [129] [130] . bHLH proteins are key regulators of tissue specific gene expression, and function by forming obligate dimers that bind through the basic DNA domains and activate transcription of target genes containing the CANNTG region in the promoter. Id proteins dimerize with these bHLH proteins, and the resultant heterodimers are unable to bind DNA and modulate transcription. Currently, four Id genes have been identified in mammals, and only Id-1 and Id-3 show ubiquitous expression [128] [129] [130] . Expression profiling analysis of BMP-9 stimulated MSCs show that the Id-1,2, and 3 genes are significantly upregulated Fig. (1C) [79] . Expression of Id genes was induced at the early stages of BMP-9 stimulation and returned to basal levels 3 days after stimulation [79] . Interestingly, both knockdown and constitutive overexpression of Id genes significantly diminished BMP-9 induced osteogenic differentiation [79] . Overexpression was also coupled with increased cell proliferation and decreased osteoblastic differentiation. Furthermore, BMP-9 induced Id expression was also shown to be dependent on Smad4 signaling [79] . These studies suggest that Id proteins likely play an important role in BMP-9 induced osteogenic differentiation, and that Id expression must be downregulated during terminal differentiation to allow the osteogenic phenotype.
Connective Tissue Growth Factor (CTGF)
Connective tissue growth factor (CTGF) is a member of the CCN (Cyr61, CTGF, and Nov) family of secreted cysteine-rich multimodular proteins [131] [132] [133] [134] [135] [136] . It plays a crucial role in embryogenesis, chondrocyte maturation, and bone formation [137] . CTGF knockout is embryo lethal, with evidence of skeletal dismorphism and decreased extracellular matrix and chondrocyte production [138] [139] [140] . In a study by Luo et al., CTGF also played a functional role in BMP-9 induced osteoblastic differentiation [80] . Expression profiling analysis of BMP-9 stimulated C3H10 stem cells demonstrated that CTGF was among the most significantly upregulated genes, even under the most stringent analysis [80] . Expression of CTGF was induced at the earliest stages of BMP-9 stimulation and returned to basal levels 5 days poststimulation. Interestingly, both siRNA knockdown and constitutive overexpression of CTGF diminished the BMP-9 mediated osteogenesis in MSCs. This indicates that a balanced regulation of CTGF expression may be crucial to the osteogenic differentiation induced by BMP-9.
Hey 1 bHLH Factor
Hey 1 is a nuclear protein belonging to the hairy/ Enhancer of split-related (HERP) family of transcriptional repressors. The HERP family of basic helix-loop-helix transcription factors are a direct target of Notch signaling, which is implicated in cell fate decision. Other important roles have included embryonic heart development, neurogenesis, and somitogenesis. Recently, gene-expression analysis conducted by Sharff et al. showed that Hey 1 (hairy/Enhancer of split-related repressor protein 1) was among the most significantly upregulated genes in BMP-9 stimulated MSCs [141] . Hey 1 was upregulated in the earliest stages of osteogenic differentiation, and chromatin immunoprecipitation analysis indicated that Hey 1 was a direct target of the BMP9-induced Smad signaling pathway [141] . Constitutive Hey 1 expression augmented BMP-9 induced matrix mineralization, while Hey 1 knockout diminished both in vitro and in vivo osteogenic differentiation [141] . Knockdown of Hey 1 is also correlated with diminished expression of the osteogenic transcription factor Runx2 [141] . In MSCs with Hey 1 knockdown, the defective osteogenic signaling could be rescued by exogenous Runx2 expression, suggesting that Runx2 is a downstream mediator of Hey 1 signaling [141] . Furthermore, a study by Kang et al. showed that Runx2 overexpression enhanced BMP-9 mediated osteogenic differentiation [71] .
CROSS-TALK BETWEEN OTHER SIGNALING PATHWAYS AND BMP-9 IN PROMOTING BONE FORMATION Wnt/ -Catenin Signaling Pathway
Wnts are a family of secreted proteins that play a crucial role in skeletal development and osteoblastic differentiation Fig. (2) [90, 100-102, 109, 142-145] . Binding of Wnts to their cognate Frizzled (Frz) and LRP-5/6 co-receptors results in activation of distinct signaling pathways, including the canonical Wnt pathway [142] . Mutations in LRP-5 affect skeletal development and bone mass deposition [146] and a recent report indicates that -catenin signaling plays various roles in fracture repair [142] . Tang et al. demonstrated that the canonical Wnt/ -catenin signaling pathway also plays a critical role in BMP-9 induced osteogenic differentiation of MSCs [142] . Wnt3a and BMP-9 enhanced each other's ability to induce alkaline phosphatase activity in MSCs while the Wnt antagonist FrzB inhibited BMP-9 induced ALP activity [142] . Chromatin immunoprecipitation analysis demonstrated that BMP-9 induced recruitment of -catenin to the osteocalcin promoter, and knockdown of -catenin caused decreased expression of late osteogenic markers in BMP-9 stimulated MSCs [142] . Finally, in vivo studies found that BMP-9 induced ectopic bone formation and matrix mineralization were significantly inhibited by FrzB overexpression or -catenin knockdown [142] . Collectively, these results suggest that the Wnt/ -catenin pathway is a crucial mediator of BMP-9 osteogenic signaling.
PPAR Transcriptional Regulator
Peroxisome proliferator-activated receptor gamma (PPAR ) is a crucial regulator of both adipogenesis and osteogenesis in MSCs [147] [148] . PPAR is able to bind fatty acid derivatives and induce differentiation of preadipocytes into terminal adipocytes [91, [149] [150] . Overexpression of PPAR in fibroblasts activates the adipogenic cascade, while PPAR knockout mice are unable to form any adipose tissue [151] [152] [153] . Furthermore, activating mutations of PPAR in humans results in increased adipogenesis and weight gain, while mutations decreasing PPAR activity result in lower BMIs [154] [155] . In BMP-9 stimulated MSCs, overexpression of PPAR promoted both osteogenic and adipogenic differentiation, and commitment to either lineages was mutually exclusive [71] . Conversely, MSCs with PPAR 2 knockdown or embryonic fibroblasts from PPAR 2 -/-mice showed a marked decrease in osteogenic differentiation and matrix mineralization upon BMP-9 stimulation, implicating PPAR as an important regulator in BMP-9 mediated osteogenesis [71] .
IGF Signaling Pathways
While BMP-9 stimulation alone causes potent osteoinduction in MSCs, studies have shown that certain factors, namely insulin-like growth factor 2 (IGF-2) and retinoic acids, can synergistically enhance this osteogenic differentiation [2, 156] . IGF-2 is a member of the IGF signaling system and plays a key role in prenatal growth and development [157] . IGF-2 signaling activates the phosphatidylinositol-3-kinase (PI3K)/AKT pathway or the mitogen-activated protein kinase pathway [158] . Chen et al. found that endogenous IGF-2 levels are relatively low in MSCs. However, exogenous expression of IGF-2 can potentiate BMP-9 induced expression of the early osteogenic marker alkaline phosphatase and late osteogenic markers osteocalcin and osteopontin [2] . IGF-2 also enhances the BMP-9 induction of BMPRSmad reporter activity and nuclear translocation of Smad 1/5/8 [2] . In vivo, IGF-2 augments BMP-9 induced ectopic Fig. (2) . BMP-9 osteogenic signaling and molecular cross-talk. BMP-9 can induce the terminal differentiation of pluripotent MSCs. This effect is potentiated by molecular cross-talk with other signaling pathways crucial to osteogenesis. [Kang, 2009] bone formation and enhances BMP-9 mediated endochondral ossification in perinatal limb explants [2] . Exogenous expression of IGFBP3, an inhibitor of IGF-2, leads to inhibition of these IGF-2 effects on osteogenesis [2] .
Retinoid Signaling Pathways
Retinoic acids (RAs) play a critical role in embryological development and maintenance of vital organs in the adult [159] [160] . RAs serve as ligands for two families of receptors, the RA receptors that bind all-trans-RA (ATRA) and the Retinoid X Receptors (RXR) that bind 9-cis-RA (9CRA) [161] [162] . RA binding to RAR/RXR causes heterodimerization and a cascade of events eventually resulting in recruitment of transcriptional activators and transcription initiation [161] . Zhang et al. examined the effect of RA signaling on BMP-9 induced osteogenic differentiation [156] . Both 9CRA and ATRA effectively induced alkaline phosphatase, osteopontin, and osteocalcin activity, and this effect was synergistic when combined with BMP-9 [156] . In mouse neonatal limb explants, RAs acted together with BMP-9 to promote expansion of the hypertrophic chondrocyte zone. Stem cell implantation studies also revealed that RAs acted synergistically with BMP9 to induce trabecular bone formation and osteoid matrix production in vivo [156] . Collectively, these results suggest that BMP-9 mediated osteogenesis likely crosstalks with the retinoic acid and/or IGF signaling pathways, and interactions with these pathways synergistically enhances osteoinduction of MSCs.
CONCLUSIONS AND FUTURE DIRECTIONS
Successful bone regeneration is critical to the effective management of bone and musculoskeletal disorders, such as fracture non-union, spinal fusion, and segmental bone loss. Currently clinical strategies have had limited success in inducing efficacious bone regeneration, underlying the need to develop adjuvant therapies. While rhBMPs 2 and 7 have shown promise in clinical studies, it had been unclear until recently whether these were the most osteogenic BMPs. Increasing evidence has shown that BMP-9 is a more potent inducer of osteogenesis in vitro and in vivo, and that BMP-9-mediated osteoinduction occurs through a different mechanism than other osteogenic BMPs.
While these studies collectively suggest that BMP-9 may serve as an adjuvant treatment for bone regeneration ( Table  1) , further investigations should be directed at the following issues: 1) How does BMP-9 function as growth/ differentiation factor during development and bone homeostasis? 2) Is BMP-9 effective in repairing bony defects in large animals and primates? 3) How can BMP-9 be effectively delivered in vivo? 4) Is it safe to administer exogenous BMP-9 in a clinically setting? Satisfactory answers to these questions would undoubtedly facilitate the transition of the BMP-9 use as a potential bone regeneration agent clinically.
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